Ann: Interim data from MSKCC study, page-22

First 22 Last

Share
Profile

Follow
Rich&Poor

1,137 Posts.

816

18/08/22

10:03

Post #: 63183208
Share

Originally posted by needle: ↑

Less likely now, as days go bye - we will get anymore on the presentation from Dr J Yang... in the short term at least.

The company has undertaken many dozens of presentations - but this time, it is the radiation CNS boss at Memorial Sloan presenting on paxalisib.

I would think this PowerPoint talk - comparing the "qualities" of paxalisib, with 3 other approved drugs - ( and the trial results, of course) - sits way ahead of anything ever from the CEO in the past.

The background slide is the thing that really appeals to me. Further to an earlier post - a third drug (in addition to Idelalisib and Alpelisib) - Everolimus is also mentioned towards the bottom of the slide........and also matched up for comparison with paxalisib. Everolimus targets the mTOR 1 and mTORC2 complex solely.

All these three drugs are FDA approved - none of them are used for CNS cancers or brain metastases.

For a period of time - I have suggested paxalisib for primary cancers also - and here we have Memorial Sloan, over the weekend.... effectively presenting a technical match up with not one or 2 - but 3 other drugs marketed for primary and blood cancers. Needless to say - that is the point from Dr Yang - he believes paxalisib comes out on top.
-----------------------

This share price is one crazy and bizarre situation - the brief discussion in this post....maybe could hardly sum up the stupidity better. Cap A$37m - cash $6m

Expand

Very disappointing and frustrating no further presentations or updates from Dr J Yang or Dr P Brastianos.
Looking forward to what the Chairman and CEO has to say in Kazia's annual report next week.

Regards.

KZA Price at posting: 24.3¢ Sentiment: Buy Disclosure: Held
6 Upvote

1 Great analysis

Reply

Top Stories

LLL

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

STN

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

TVN

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

RHI

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

KGL

KGL sniffs 19% Cu from drilling at Rockface play in NT

Climate change to drive market trends to the moon

ITM

Fast-track assaying yields 182 g/t gold for iTech at new NT play

There are more pages in this discussion • 26 more messages in this thread...

First 22 Last

Add KZA (ASX) to my watchlist

Ann: Interim data from MSKCC study, page-22

Top Stories

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

KGL sniffs 19% Cu from drilling at Rockface play in NT

Climate change to drive market trends to the moon

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Featured News